A mutant strain of Streptomyces peucetius produced an anthracycline antibiotic whose structure has been established to be 4-O-demethyl-l3-dihydrodaunorubicin (4), by application of spectroscopic methods and chemical degradation.
Biosynthesis and Isolation of 4-O-Demethyl-13-dihydrodaunorubicin (4)
The anthracycline glycoside 4 has been isolated from the mycelium of a mutant strain of Strepto- 
Structure Determination
The UV and visible spectra of compound 4 were similar to those of carminomycin (2) and of carminomycin (2).
3) The general appearance of the PMR spectrum of compound 4 both as free base and as hydrochloride was similar to that of 13-dihydrodaunorubicin (3, daunorubicinol)4~7) the only difference being the absence of the methoxy signal and the presence of an additional phenolic OH signal. Mild acid hydrolysis afforded a red aglycone (7) and an aminotrideoxysugar, C6H13O3N, which was identified as daunosamine (3-amino-2,3,6-trideoxy-L-lyxo-hexose)8) by direct comparison with an authentic sample. The aglycone (7) showed IR ( Fig. 2 ), UV and visible spectra very similar to those of the parent glycoside and the analytical data indicated a molecular formula C20H18O8 (M.W. 386.36)
confirmed by mass spectrometry. The attachment of the sugar moiety to the benzylic C-7 position was established by catalytic hydrogenolysis of the glycoside, under these conditions daunosamine and a deoxyaglycone (8) were obtained. Compound 8 had a molecular formula of C20H18O7 (M.W. 370), confirmed by mass spectrometry. Catalytic hydrogenolysis of the aglycone (7), gave a compound undistinguishable from 8, which was identified as 4-O-demethyl-7-deoxy-13-dihydrodaunomycinone.
The IR and mass spectra of compound 8 were comparable to those of demethyl-deoxydaunorubicinol aglycone reported by TAKANASHI and BACHUR.9) Thus the structural formula of glycoside 4, corresponding to 4-O-demethyl-13-dihydrodaunorubicin (4-O-demethyldaunorubicinol, 13-dihydrocarminomycin) may be proposed. After completion of the present work preparations of 13-dihydrocarminomycin (4) by chemical and microbiological reduction of carminomycin (2) were reported.10,11) Further evidence supporting the structure proposed for compound 4 was obtained by comparison of its aglycone (7) with a sample 
Biological Activity
The antitumor activity of 4-O-demethyldaunorubicin (carminonrycin I, 2) and of its 13-dihydro derivative (4) was compared with those of daunorubicin (1) and of 13-dihydrodaunorubicin (3) in experimental systems in vitro and in vivo. The results are reported in Tables 2 and 3 . As previously reported"', 13-dihydrodaunorubicin (daunorubicinol, 3) was less effective than daunorubicin (1) on HeLa cells in vitro. In L1210 leukemia-bearing mice, 13-dihydrodaunorubicin showed a range of active doses similar to that of daunorubicin.
4-O-Demethyldaunorubicin (carminomycin, 2) was about two-times more active than daunorubicin on HeLa cells cloning efficiency while in L1210 leukemia it exerted an antitumor activity similar to that of daunorubicin at about five-times the lower dose. 
